US 11673953
DLL3 targeting chimeric antigen receptors and binding agents
granted A61KA61K2039/505A61K2239/31
Quick answer
US patent 11673953 (DLL3 targeting chimeric antigen receptors and binding agents) held by Allogene Therapeutics, Inc. expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Allogene Therapeutics, Inc.
- Grant date
- Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 31
- CPC classes
- A61K, A61K2039/505, A61K2239/31, A61K2239/38, A61K2239/55